Clinical trials: CD7+ Acute Leukemia
Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY035 cell injection in the treatment of patients with CD7-positive relapsed or…
- Conditions
- Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory, Acute Myeloid Leukemia (AML), T Cell Lymphoma
- Trial name
- NCT07784309
- Testing
- HY035 cell injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
T Cell Lymphoma, T Cell Leukemia
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies.
- Conditions
- T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoma of CNS
- Trial name
- BAH246 (NCT06420076)
- Testing
- CD5/CD7 CAR-T
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech